RCS - Genflow Biosciences - Key SIRT6 Patent Application

Genflow BiosciencesAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250515:nRSO7021Ia&default-theme=true

RNS Number : 7021I  Genflow Biosciences PLC  15 May 2025

15 May 2025

 

Genflow Biosciences plc

 

Genflow Biosciences Announces Progress of Key SIRT6 Patent Application in
Japan

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"),
the only publicly listed longevity company in Europe, announces that the
Japanese Patent Office has advanced its SIRT6-related patent application
(Application No. JP 2024515284) to the national examination phase.

 

The application, titled "Variants of SIRT6 for Use in Preventing and/or
Treating Age-Related Diseases," was originally filed on 13 May 2022 and is
jointly owned by the University of Rochester, The Trustees of Columbia
University in the City of New York, and Albert Einstein College of Medicine.
Genflow holds the exclusive license to this intellectual property.

 

The invention covers novel SIRT6 gene variants that play a central role in
genomic stability, metabolic regulation, and healthy aging. These variants
underpin Genflow's core therapeutic platform and represent a key part of its
pipeline targeting age-related diseases.

 

The progression to national examination in Japan marks an important step in
Genflow's strategy to establish broad international patent protection. Japan,
with one of the world's most rapidly aging populations, is a priority market
for longevity-related innovation.

 

Dr. Eric Leire, CEO of Genflow Biosciences, commented: "We are pleased to see
continued momentum in the protection of our SIRT6 intellectual property. Japan
represents a strategically important jurisdiction for Genflow, and advancing
this patent application strengthens our global positioning as a leader in
longevity gene therapy."

 

Genflow continues to progress its preclinical and clinical programs targeting
age-related pathologies using the SIRT6 gene variants.

 

Contacts

 Genflow Biosciences                           Harbor Access
 Dr Eric Leire, CEO                            Jonathan Paterson, Investor Relations
 +32-477-495-881                               +1 475 477 9401
                                               Jonathan.Paterson@Harbor-access.com
 Corporate Brokers
 Capital Plus Partners Ltd
 Jon Critchley, +44 0203 821 6168

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Expected to begin in 2025, Genflow's clinical trial aims to explore
the potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn and Twitter/X.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZGMKDDNGKZM